The recent window is materially active
235 eligible papers appear in the current 30-day evidence window, compared with 51 in the prior 30 days. The busiest visible day is 2026-04-22 with 18 eligible papers.
4.6x prior-window volumeWeekly trend brief
Long COVID follow-up is clustering around brain, inflammation, and quality-of-life evidence. The current 30-day evidence window contains 235 eligible papers, 4.6x the prior 30-day window, with 235 abstract-backed papers available for a closer scan. Representative papers point to neurological symptoms, inflammatory protein signals, quality-of-life cohorts, pediatric case series, and veteran population studies.
235 eligible papers appear in the current 30-day evidence window, compared with 51 in the prior 30 days. The busiest visible day is 2026-04-22 with 18 eligible papers.
4.6x prior-window volume235 recent papers include abstracts, about 100% of the eligible set. That gives the brief enough signal for topic-specific commentary while keeping claims limited to paper metadata and representative titles.
235 abstract-backed papersThe selected papers point toward neurological symptoms, inflammatory protein signals, quality-of-life cohorts, pediatric case series, and veteran population studies. That gives the brief a visible research direction rather than only a ranked list of recent papers.
8 representative papers8 representative papers span 7 sources.
7 representative sourcesBrain pathology, neuropsychiatric symptoms, inflammatory proteins, and pediatric neuroimaging give this page a clear clinical follow-up theme.
8 representative papersLongitudinal and socioeconomic quality-of-life papers help connect symptom evidence to patient burden rather than only acute infection history.
8 representative papersVeteran, pediatric, and adolescent studies broaden the review set beyond one clinic population.
8 representative papersSelected because it anchors the clinical follow-up theme around neurologic, inflammatory, quality-of-life, or cohort evidence; this paper appears in Brain Pathology (2026) and is matched to Long-Term Effects of COVID-19.
Selected because it anchors the clinical follow-up theme around neurologic, inflammatory, quality-of-life, or cohort evidence; this paper appears in F1000Research (2026) and is matched to Long-Term Effects of COVID-19.
Selected because it anchors the clinical follow-up theme around neurologic, inflammatory, quality-of-life, or cohort evidence; this paper appears in PLoS ONE (2026) and is matched to Long-Term Effects of COVID-19.
Selected because it anchors the clinical follow-up theme around neurologic, inflammatory, quality-of-life, or cohort evidence; this paper appears in Communications Medicine (2026) and is matched to Long-Term Effects of COVID-19.
Selected because it anchors the clinical follow-up theme around neurologic, inflammatory, quality-of-life, or cohort evidence; this paper appears in PLoS ONE (2026) and is matched to Long-Term Effects of COVID-19.
Selected because it anchors the clinical follow-up theme around neurologic, inflammatory, quality-of-life, or cohort evidence; this paper appears in The Neuroradiology Journal (2026) and is matched to Long-Term Effects of COVID-19.
Selected because it anchors the clinical follow-up theme around neurologic, inflammatory, quality-of-life, or cohort evidence; this paper appears in Journal of Shahid Sadoughi University of Medical Sciences (2026) and is matched to Long-Term Effects of COVID-19.
Selected because it anchors the clinical follow-up theme around neurologic, inflammatory, quality-of-life, or cohort evidence; this paper appears in Frontiers in Public Health (2026) and is matched to Long-Term Effects of COVID-19.